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Background
NO/cGMP-mediated signal transduction is involved in
synaptic plasticity in various brain regions. NO effects
are transduced by the NO receptor guanylyl cyclase
( N O - G C )t h a te x i s t si nt w oi s o f o r m s ,N O - G C 1a n d
NO-GC2, with indistinguishable regulatory properties.
Mice deficient in either NO-GC1 or NO-GC2 revealed
that both NO-GC isoforms are required for LTP indi-
cating the existence of two separated NO/cGMP path-
ways. Recently, we demonstrated a presynaptic role of
NO/cGMP in facilitation of glutamate release and
indentified eNOS and NO-GC1 as the participating
enzymes. Yet, the involved cGMP-hydrolysing phospho-
diesterases (PDE) remained unknown.
Results
Here we demonstrate that PDE2 accounts for 50% of
cGMP-hydrolysing activity in hippocampal homoge-
nates. In hippocampal slices of WT, NO-GC1 and NO-
GC2 KO mice, PDE2 inhibition increased NMDA-
induced cGMP levels.
Conclusion
This suggests PDE2 as a component of both NO-GC1-
and NO-GC2-mediated signalling pathways. Moreover
we analyzed the physiological role of the PDE2 on gluta-
matergic transmission in the hippocampal CA1 region
by single-cell recordings in acute slices.
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